Is Methamphetamine-Linked Cardiomyopathy an Emerging Epidemic for New Generation?

Azka Latif, Muhammad Junaid Ahsan, Noman Lateef, Vikas Kapoor, Scott Lundgren, Muhammad Zoraiz Ahsan, Soban Ahmad, Mohsin Mirza

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


The use of methamphetamines is growing worldwide with cardiovascular disease as the leading cause of mortality and morbidity. Long-term use of methamphetamines is associated with malignant hypertension, myocardial ischemia, pulmonary hypertension, and methamphetamines-associated cardiomyopathy. These effects are noted to be dose-dependent and potentially reversible with discontinuation of methamphetamines in the early stages when there is limited or no myocardial fibrosis. This review aims to (1) summarize the available data from epidemiologic studies, (2) describe pathophysiological mechanisms and clinical presentation, (3) Management of methamphetamines induced cardiomyopathy and potential complications associated with it, and (4) Strategies to reduce methamphetamines abuse and related hospitalization.

Original languageEnglish (US)
Article number101042
JournalCurrent Problems in Cardiology
Issue number1
StatePublished - Jan 2023

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Is Methamphetamine-Linked Cardiomyopathy an Emerging Epidemic for New Generation?'. Together they form a unique fingerprint.

Cite this